Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Madelaine-Chambrin

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Annales Pharmaceutiques Francaises|February 2, 2006
[Characteristics of clinical trials in oncology: pharmacist's implication]I Madelaine-Chambrin
Annales Pharmaceutiques Francaises|January 1, 1996
[Current therapeutic methods in onco-hematology]I Madelaine-Chambrin, V Piquet-Sevrin, P Faure
Medecine Et Maladies Infectieuses|October 24, 2007
[Traceability of a resorbable implant for lipoatrophy: why should it be traced and how should this be done? Example of polylactic acid (Newfill)]C Dupont, M Lafaurie, I Madelaine-Chambrin, et al.
Clinical Biochemistry|December 1, 2005
Quantification of urinary allantoin by capillary zone electrophoresis during recombinant urate oxydase (rasburicase) therapyD Kattygnarath, N Mounier, I Madelaine-Chambrin, et al.
Hematological Oncology|December 28, 2024
One-Day Brentuximab-Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin LymphomaH Moatti, P Brice, M-C Laroque, et al.
Leukemia|July 23, 2004
A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patientsP Rousselot, J Larghero, B Arnulf, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Annales Pharmaceutiques Francaises|February 2, 2006
[Characteristics of clinical trials in oncology: pharmacist's implication]I Madelaine-Chambrin
Annales Pharmaceutiques Francaises|January 1, 1996
[Current therapeutic methods in onco-hematology]I Madelaine-Chambrin, V Piquet-Sevrin, P Faure
Medecine Et Maladies Infectieuses|October 24, 2007
[Traceability of a resorbable implant for lipoatrophy: why should it be traced and how should this be done? Example of polylactic acid (Newfill)]C Dupont, M Lafaurie, I Madelaine-Chambrin, et al.
Clinical Biochemistry|December 1, 2005
Quantification of urinary allantoin by capillary zone electrophoresis during recombinant urate oxydase (rasburicase) therapyD Kattygnarath, N Mounier, I Madelaine-Chambrin, et al.
Hematological Oncology|December 28, 2024
One-Day Brentuximab-Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin LymphomaH Moatti, P Brice, M-C Laroque, et al.
Leukemia|July 23, 2004
A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patientsP Rousselot, J Larghero, B Arnulf, et al.
Pageof 1